Doctor-
Thanks for your post.
For Kaposi's sacroma that's limited to the skin (no visceral involvement), treatment with HAART is often sufficient to effect "cure"-- to this extent your right on track.
The combination of d4T (Zerit), ddI (Videx) and nelfinavir (Nelfinavir) would not be one of my recommendations for a variety of reasons. First, d4T is no longer either preferred or alternate on DHHS guidelines; further the combo of d4T and ddI, once very popular, is not recommended because of increased risk of drug-related adverse reactions (pancreatitis, peripheral neuropathy and lactic acidosis). Nelfinavir (also once very popular for first-line treatment) has fallen from favor because of side effect profile (diarrhea) and the inability to boost the medication (with ritonavir).
Current
DHHS treatment guidelines give good guideance for contemporary "preferred" and "alternate" options. Most new regimens are dosed once-daily, using fixed-dose combination nucleosides with either efavirenz (Susitva, Stocrin) or a boosted protease inhibitor (lopinavir/ritonavir, atazanavir/ritonavir or fosamprenavir/ritonavir).
I hope this is a useful starting point. Feel free to write me back here with any follow up questions. BY